<DOC>
	<DOCNO>NCT02449330</DOCNO>
	<brief_summary>This clinical trial design assess cardiac diastolic function long term treatment teneligliptin compare without teneligliptin patient type 2 diabetes mellitus two arm ; one include patient show E/e ' echocardiography less 8 , include patient show E/e ' echocardiography 8 .</brief_summary>
	<brief_title>Teneligliptin Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Asians age 20 85 year old baseline Patients type 2 diabetes mellitus include either A ) B ) criterion . A ) Patients necessary start treatment use antidiabetic agent ( ) change antidiabetic agent ( ) . B ) Patients possible change antidiabetic agent ( ) . Patients leave ventricular ejection fraction 40 % Patients write informed consent Patients type 1 diabetes mellitus Patients slowly progressive type 1 diabetes mellitus positive pancreatic islet relate autoimmune antibody GAD antibody IA2 antibody ICA antibody Patients diabetes mellitus cause evident genetic factor Patients diabetes mellitus cause secondary factor endocrine disease liver disease Patients diabetic ketoacidosis hyperosmolar hyperglycemic syndrome Patients severe infectious disease plan surgical treatment suffer severe trauma Patients severe liver dysfunction Patients hypophyseoprivic adrenal insufficiency Patients malnutrition starve state irregular caloric intake calorie insufficiency hyposthenia Patients judge unsuitable study planning exercise intensively Patients judge unsuitable study may drink excessively abuse drug Patients show QT prolongation electrocardiogram Patients past history heart failure show NYHA classification grade 3 baseline Patients past history acute coronary syndrome coronary intervention cardiac surgery develop within 6 month Patients surgical past history mitral valve replacement mitral valve repair severe calcification mitral valve Patients already treat Teneligliptin Women breastfeed Pregnant woman patient possibility pregnancy Patients expect live less 3 year Patients past history drug hypersensitivity Teneligliptin Patients already involve interventional clinical trial plan involved Patients judge inappropriate study doctor charge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>